Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.84
EPS est.
$-0.70
EPS surprise
-19.32%
1-day move
-0.94%
BridgeBio Pharma's earnings report showed a larger-than-expected loss per share, which contributed to a slight decline in the stock price. The lack of revenue data and guidance may leave investors uncertain about the company's future performance. The stock's reaction reflects cautious sentiment among investors following these results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.84 | $-0.67 | -19.32% |
| Revenue | — | $179M | — |
No transcript is on record, and the analysis is based solely on numerical results.
BridgeBio Pharma, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancers. With a market cap of $13 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs through innovative treatments.
Last quarter
In the last quarter, BridgeBio reported an EPS of $-1.00, missing expectations by 34%. The stock saw a slight increase of 0.59% the following day.
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-13.74%
Avg 1-day reaction
+0.42%
Analysts expect BridgeBio to report a loss of $-0.67 per share on revenues of $179 million for Q1-2026. The market is closely watching for any signs of improvement in financial performance.
Bull case
If BridgeBio can exceed revenue expectations and show progress in its drug development pipeline, it could lead to a positive market reaction.
Bear case
Conversely, if the company reports a larger loss than expected or fails to provide a clear path to profitability, it may face significant downward pressure on its stock.
Key metrics to watch
EPS
$-0.67Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$179MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the company provide any updates on its drug pipeline or upcoming trials?
Investors are keen to hear about advancements in the pipeline, which could impact future revenue and growth potential.
Q2
How does management plan to address the recent trend of EPS misses?
Understanding management's strategy to improve financial performance is crucial for investor confidence.
Est. EPS
$3.70
Est. Rev
$3.9B
Impl. Move
±4.7%
Why consensus could be wrong
The Street may be underestimating the potential for BridgeBio's pipeline to deliver unexpected positive results, which could lead to better-than-expected revenue.
Supporting evidence
The options market is pricing an 8.62% move, suggesting higher volatility than historical averages.
BridgeBio's recent insider selling could indicate a lack of confidence in the near-term outlook, which contrasts with potential positive developments in the pipeline.
Key risk
If the company announces significant progress in its clinical trials, it could shift sentiment dramatically.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a pattern of missed earnings expectations, and investors are looking for signs of recovery.
Bull confirmed if
A revenue figure exceeding $196 million would confirm the bull case.
Bear confirmed if
An EPS loss greater than $-0.84 would reinforce the bear case.
What the market is pricing for the move.
Implied Move
±8.62%
Historical Avg
±2.1%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±8.6% while BBIO has averaged ±2.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
41.0%
Smart-money positioning from the most recent 13F filings.
Institutional
99.57%
of float
Insider
3.91%
of float
Holders
646
institutions
Top Holders· as of Jun 2026
Jupiter Topco LLC
14,110,278 sh · $938.3M
7.22%
100.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If BridgeBio beats expectations, history suggests the stock could rise by around 2.09%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see minimal movement as investors await further guidance.
Miss
A miss could lead to a decline of approximately 2.39%, reflecting ongoing concerns about the company's financial health.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Kohlberg Kravis Roberts & Co. L.P.
13,260,971 sh · $881.9M
6.78%
Flat
Farallon Capital Management LLC
10,743,063 sh · $714.4M
5.50%
14.7%
Blackrock Inc.
10,287,156 sh · $684.1M
5.26%
-27.6%
Viking Global Investors, L.P.
9,949,219 sh · $661.6M
5.09%
-16.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded May 11, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.